CENTURY THERAPEUTICS INC · Data as of 2026-09-08
2026
· Additional insights from ongoing CARAMEL IST expected in 2026: The company anticipates updated preliminary clinical data this year from the ongoing CARAMEL study, a Phase 1/2 investigator-sponsored trial (IST) led by Professors Georg Schett and Andreas Mackensen and sponsored by the Friedrich-Alexander University Erlangen-Nürnberg.Source filing
4Q 2026
CNTY - 813, Century's type 1 diabetes iPSC-derived islet therapy with functional - cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027Source filing
Q4 2026
We continue to advance CNTY-813 through IND-enabling studies and expect to submit an IND for CNTY-813 in the fourth quarter of 2026 and anticipate initial clinical data in the second half of 2027, subject to completion of remaining IND-enabling studies and regulatory clearance.Source filing
2H 2027
CNTY - 813, Century's type 1 diabetes iPSC-derived islet therapy with functional - cure potential, remains on track for IND in 4Q 2026; initial clinical data expected in 2H 2027Source filing
H2 2027
We continue to advance CNTY-813 through IND-enabling studies and expect to submit an IND for CNTY-813 in the fourth quarter of 2026 and anticipate initial clinical data in the second half of 2027, subject to completion of remaining IND-enabling studies and regulatory clearance.Source filing
Oct 2
62 nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026; Milan, Italy; Presentation #225, Paris Hall, October 2 nd , 2026, 10-11 AM CEST)Source filing
Oct 9
Breakthrough T1D ® Clinical & Research Congress 2026 (CRC 2026; Philadelphia, Pennsylvania; Presentation #341, Hall 1, October 9 th , 2026, 3:50- 4:50 PM EST)Source filing